

# TABLE OF CONTENTS

May 19, 2008

No. 2090

## BUSINESS

- 1 Bayer to Grow Twice as Fast as Market Aiming at Sales of ¥200 Bil.: President J-L Lowinski
  - Oncology to Account for 1/4 of Sales in 5-10 Years
  - Training English-proficient MRs
- 3 Pletaal Launched in Sweden: Otsuka
- 4 Takeda: Heavy R&D Costs Cut Operating Profits
  - Tender Offer for Millennium Completed
- 4 DSP: Operating Profits Down 12.6% due to Increases in R&D Costs
- 5 MTPC: Remicade Continues Strong Growth
- 6 Santen: Overseas Sales Account for 14.3% of Total Sales
- 6 Kyowa Hakko: Sales Up 10.7% to ¥392 Bil.
- 7 Bonalon Drives Teijin's Pharma Business
- 7 Asahi Kasei Pharma: Sales Up 6.5% to ¥111.2 Bil.
- 7 **NEW PRODUCT**
  - Sanofi-aventis: Clexane Kit for SC Injection
- 8 Women's Healthcare Team to Lead Marketing of Lunabell: Nippon Shinyaku
- 8 Sugi Pharmacy to Adopt Holding Company System
- 9 **BUSINESS NEWS IN BRIEF**
  - Fuso to Recall 360,000 Units of Heparin Products
  - Ito Ham Sciences Recalls LMW Heparin Product
  - Eisai Wins Appeal on Anti-dementia Medicines in UK
- 9 *Koroshō* to Hear 20 Wholesalers in May
  - Abbott Japan Transfers Its Pharma Business Division to Tokyo

## REGULATORY

- 10 Committee Recommends Approval of Pfizer's Macugen
  - Recommendation of Approval for Astellas' Ramosetron Withheld
  - Approval of Terumo's Combined Antagonist of Muscle Relaxant Petitioned by Healthcare Providers
  - Natalizumab to Be Designated as Orphan Drug
- 11 Banyu's Isentress Roughly Recommended for Approval
- 12 Daiichi Sankyo to Apply for Combination of Olmetec and Calblock
- 13 Divergent Opinions on Japanese Version of FDA among LDP Members
- 13 Life Science Summit Calls For Creation of Japanese Version of FDA, NIH, OSCHR
- 14 *Koroshō* to Consider Creating Japanese Version of FDA
- 14 JMA Has Not Yet Decided on Its Stance Regarding the FPMAJ's Pricing System Reform Proposal: Dr Takeshima

## 14 Commentary

- Shaking Pharmaceutical Administration System
- 16 Prof. H. Endo Elected Chairman of *Chuikyo*
- 16 **REGULATORY NEWS IN BRIEF**
  - AMITIZA Approved to Treat IBS-C in the US: Takeda
  - Mycamine Approved in EU: Astellas
  - Taflotan Approved for Glaucoma in Denmark: Santen
  - FK506 Modified Release Formulation Receives Approvable Letter for Liver Transplants from FDA: Astellas
  - FDA Advisory Committee Votes in Favor of Fospropofol: Eisai
  - AstraZeneca Applies for Iressa in EU
  - Agranulocytosis Added as Serious ADR of Carbapenem

## 12 ON THE MOVE

- A. G. Zulueta Appointed President of Eli Lilly Japan
- Ikuo Ogihara to Resign, Itaru Kojo to Succeed as President of Kyorin

## COMMENTARY

- 18 **Maurer's Healthcare Insight (95)**
  - Will Japan Reward Innovation?: P. Reed Maurer
- 18 **Obituary**
  - Dr Yutaka Mizushima: Former Chairman of LTT-Bio Pharma

## GENERIC

- 20 Nihon Chouzai Promotes Dispensing of Generics
  - Operating Profits Up 48%

## 20 TOPICS

- Mylan Accepted as JPMA Member
- 21 Will Generics Take Off? (3)
- 22 **GENERIC NEWS IN BRIEF**
  - MTPC to Tie Up with Choseido in Generic Drug Business
  - Towa Pharm. Revises Business Forecast Downward
  - New System Not Causing Any Problem: JMA Vice President

## R&D

### 23 R&D NEWS IN BRIEF

- Immunomodulator Jointly Discovered by DSP and AZ Enters PI

## MEDICAL DEVICES

### 23 MEDICAL DEVICE NEWS IN BRIEF

- Olympus: Medical Business Div. Drives Overall Performance
- Medi-Physics Starts Operating New Lab in Tohoku Region